Letter to the FDA on statins
FDA-Statins-Letter-11-16-07.pdf
|
211.7 kB
November 16, 2007
CU believes such review should involve a formal systematic analysis of existing studies
and a benefit-risk analysis targeted primarily at the "primary-prevention" population.
and a benefit-risk analysis targeted primarily at the "primary-prevention" population.